NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

South Korea’s Constitutional Court will hold another hearing next week before deciding whether President Yoon Suk Yeol should be permanently removed from office for his ill-fated martial law declarati ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 89 tables and 75 figures, this 178-page report ?North America Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 148 tables and 111 figures, this 241-page report ?Global Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...